Literature DB >> 10230854

Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes.

J Kimura1, M Kawahara, E Sakai, J Yatabe, H Nakanishi.   

Abstract

We investigated effects of a novel cardioprotective drug, JTV-519 (4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahy dro-1,4-benzothiazepine monohydrochloride) on membrane currents of guinea pig ventricular myocytes by whole-cell voltage and current clamp methods. The fast Na+ current (iNa) was activated by ramp pulses from various holding potentials of -90, -80 or -60 mV to 10 mV with various intervals. At 0.2 Hz, JTV-519 inhibited iNa in a concentration-dependent manner with an IC50 of approximately 1.2 and 2 microM at the holding potential of -60 and -90 mM, respectively, implicating a voltage-dependent block. Increasing the pulse frequency from 1 to 2 or 3.3 Hz in the presence of 1 microM JTV-519 shortened the time-course and increased the level of iNa block, indicating a frequency-dependent block. The time-course of iNa blocking by JTV-519 was slower than that of lidocaine and similar to that of quinidine. Ca2+ current (iCa) and the inwardly rectifying K+ current (iK1) were also inhibited by JTV-519. JTV-519 decreased the duration and the height of the plateau of the action potential. We conclude that JTV-519 has frequency- and voltage-dependent blocking effects on iNa as well as inhibition of iCa and iK1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230854     DOI: 10.1254/jjp.79.275

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  26 in total

1.  JTV-519, a novel cardioprotective agent, improves the contractile recovery after ischaemia-reperfusion in coronary perfused guinea-pig ventricular muscles.

Authors:  K Ito; S Shigematsu; T Sato; T Abe; Y Li; M Arita
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  CGP-37157 inhibits the sarcoplasmic reticulum Ca²+ ATPase and activates ryanodine receptor channels in striated muscle.

Authors:  Jake T Neumann; Paula L Diaz-Sylvester; Sidney Fleischer; Julio A Copello
Journal:  Mol Pharmacol       Date:  2010-10-05       Impact factor: 4.436

3.  Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts.

Authors:  H Nakaya; Y Furusawa; T Ogura; M Tamagawa; H Uemura
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Synchronous systolic subcellular Ca2+-elevations underlie ventricular arrhythmia in drug-induced long QT type 2.

Authors:  Jong J Kim; Jan Němec; Qiao Li; Guy Salama
Journal:  Circ Arrhythm Electrophysiol       Date:  2015-02-26

5.  Effect of K201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes.

Authors:  Y-J Chen; Y-C Chen; W Wongcharoen; C-I Lin; S-A Chen
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 6.  Ryanodine receptor patents.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Recent Pat Biotechnol       Date:  2012-12

7.  Bradycardia alters Ca(2+) dynamics enhancing dispersion of repolarization and arrhythmia risk.

Authors:  Jong J Kim; Jan Němec; Rita Papp; Robert Strongin; Jonathan J Abramson; Guy Salama
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-11       Impact factor: 4.733

Review 8.  Calcium cycling proteins and heart failure: mechanisms and therapeutics.

Authors:  Andrew R Marks
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

9.  K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum.

Authors:  Karl Toischer; Stephan E Lehnart; Gero Tenderich; Hendrik Milting; Reiner Körfer; Jan D Schmitto; Friedrich A Schöndube; Noboru Kaneko; Christopher M Loughrey; Godfrey L Smith; Gerd Hasenfuss; Tim Seidler
Journal:  Basic Res Cardiol       Date:  2009-08-30       Impact factor: 17.165

Review 10.  Pharmacological characteristics and clinical applications of K201.

Authors:  Noboru Kaneko; Ryuko Matsuda; Yoshihito Hata; Ken Shimamoto
Journal:  Curr Clin Pharmacol       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.